Preliminary experiments showed that the inhibitor potently inhibited AKT activity, as measured by de-phosphorylation of GSK3α/β, in CLL cells after incubation for 24 h under standard conditions with an estimated IC50 of 3 μM (Supplementary Figure 1A and 1B). This evidence concerns the gene GSK3A and B-cell chronic lymphocytic leukemia.